Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study

To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK received CT-P13 at a starting dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 46. They were follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Eun Hye, Lee, Eun Young, Lee, Yun Jong, Ha, You Jung, Yoo, Wan-Hee, Choi, Byoong Yong, Paeng, Jin Chul, Suh, Hoon Young, Song, Yeong Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223861/
https://www.ncbi.nlm.nih.gov/pubmed/30229280
http://dx.doi.org/10.1007/s00296-018-4159-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223861/
https://www.ncbi.nlm.nih.gov/pubmed/30229280
http://dx.doi.org/10.1007/s00296-018-4159-1

Ejemplares similares